Loading...
Most patients with early- and advanced-stage classic Hodgkin lymphomas (HLs) are cured by present-day combination chemotherapy regimens or chemotherapy plus involved-field radiation. Finding reliable markers that help predict likelihood of response to therapy might allow clinicians to individualize patients' treatments. With this goal, investigators utilized gene expression profiling to identify biomarker signatures in lymph node samples from 130 HL patients and then retrospectively correlated those signatures with patients' outcomes.
The presence of gene expression signatures characteristic of tumor-associated macrophages correlated highly with treatment failure. This finding was validated in a second, independent cohort of 166 HL patients.…